Klinik Araştırma
BibTex RIS Kaynak Göster
Yıl 2023, Cilt: 4 Sayı: 4, 601 - 609, 12.02.2024
https://doi.org/10.46871/eams.1419727

Öz

Kaynakça

  • 1. Nambiar AK, Arlandis S, Bø K, et al. European association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. European Urology. 2022;82(1):49-59.
  • 2. Wróbel AF, Kluz T, Surkont G, et al. Novel biomarkers of overactive bladder syndrome. Ginekologia Polska. 2017;88(10):568-73.
  • 3. Bhide AA, Cartwright R, Khullar V, et al. Biomarkers in overactive bladder. International urogynecology journal. 2013;24:1065-72.
  • 4. Gill K, Horsley H, Swamy S, et al. A prospective observational study of urinary cytokines and inflammatory response in patients with Overactive Bladder Syndrome. BMC urology. 2021;21:1-7.
  • 5. Ghoniem G, Faruqui N, Elmissiry M, et al. Differential profile analysis of urinary cytokines in patients with overactive bladder. International urogynecology journal. 2011;22:953-61.
  • 6. Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. International urology and nephrology. 2010;42:629-35.
  • 7. Haylen BT, De Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourology and Urodynamics: Official Journal of the International Continence Society. 2010;29(1):4-20.
  • 8. Tarcan T, Mangır N, Özgür MÖ, et al. OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni. 2012;21(21):113-6.
  • 9. Saini R, Gonzalez RR, Te AE. Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. Current urology reports. 2008;9(4):314-9.
  • 10. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology. 2006;50(6):1306-15.
  • 11. Benli E. An examination of relationship between overactive bladder and C-reactive protein and erythrocyte sedimentation rate. The New Journal of Urology. 2023;18(1):33-40.
  • 12. Kupelian V, Rosen RC, Roehrborn CG, et al. Association of overactive bladder and C‐reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU international. 2012;110(3):401-7.
  • 13. Çulha MG, Değirmentepe RB, Özbir S, et al. Elevated neutrophil-to-lymphocyte ratio may be associated with overactive bladder patients. European Archives of Medical Research. 2020;36(2):125-9.
  • 14. Kim S, Park JH, Oh YH, et al. Correlation between neutrophil to lymphocyte ratio and overactive bladder in South Korean women: a community-based, cross-sectional study. BMJ open. 2021;11(10):e048309.
  • 15. Tyagi P, Tyagi V, Qu X, et al. Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. American Journal of Physiology-Renal Physiology. 2016;311(3):F548-F54.
  • 16. Pennycuff JF, Schutte SC, Hudson CO, et al. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder. Neurourology and urodynamics. 2017;36(3):740-4.
  • 17. Inamura S, Ito H, Shinagawa T, et al. Serum C‐reactive protein level is not associated with prostatic inflammation but with overactive detrusor in patients with benign prostatic hyperplasia. Neurourology and Urodynamics. 2019;38(6):1728-36.

INVESTIGATION OF INFLAMMATORY MARKER LEVELS IN OVERACTIVE BLADDER PATIENTS

Yıl 2023, Cilt: 4 Sayı: 4, 601 - 609, 12.02.2024
https://doi.org/10.46871/eams.1419727

Öz

Aim: To investigate whether inflammation plays a role in the pathogenesis of patients diagnosed with overactive bladder (OAB).
Material-Method: Patients who applied to the urology outpatient clinic with a preliminary diagnosis of OAB between March 2022 and September 2023 and were diagnosed were prospectively included in the study. Demographic data of the patients, such as age, gender and body mass index (BMI), were recorded. The number of urgency attacks, pollakiuria and nocturia, OAB-V8 scores (0-40) and the anticholinergics used were recorded. Blood group, whole blood and biochemical values measured from peripheral blood at outpatient clinic admissions, among the inflammation markers neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), C reactive protein/albumin (CRP/Albumin) ratio and Deritis (AST/ALT) ratios were recorded.
Patients with urinary tract infection, renal function test abnormalities, and patients with a history of previous urological surgery were excluded from the study. Patients who presented to the outpatient clinic with non-OAB were included as the control group. Hemogram and biochemical values of these patients were also recorded.
Data recorded at baseline were compared between groups.
Results: A total of 198 patients were included in the study (OAB group n: 99, control group n: 99). The mean age of all patients was 52.3±15 years, and the mean OAB-V8 score was 11.9±9.9.
No statistically significant difference was observed between the groups in terms of gender and blood group. No statistically significant difference was observed between the groups in terms of hemoglobin, hematocrit, lymphocyte, platelet, AST, ALT, albumin, NLR, LMR, PLR, Deritis, MLR and CRP/albumin ratio. The mean age of the OAB group was found to be significantly higher than the control group (p<0.001). The mean WBC, neutrophil, monocyte and CRP values of the control group were found to be statistically significantly higher than the OAB group.
As a result of the multivariate analysis, only age was found to be a predictor for OAB.
Conclusion: Although inflammation is thought to play a role in the pathogenesis of OAB, according to the results of our study, inflammation markers were found to be low in OAB patients.

Kaynakça

  • 1. Nambiar AK, Arlandis S, Bø K, et al. European association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. European Urology. 2022;82(1):49-59.
  • 2. Wróbel AF, Kluz T, Surkont G, et al. Novel biomarkers of overactive bladder syndrome. Ginekologia Polska. 2017;88(10):568-73.
  • 3. Bhide AA, Cartwright R, Khullar V, et al. Biomarkers in overactive bladder. International urogynecology journal. 2013;24:1065-72.
  • 4. Gill K, Horsley H, Swamy S, et al. A prospective observational study of urinary cytokines and inflammatory response in patients with Overactive Bladder Syndrome. BMC urology. 2021;21:1-7.
  • 5. Ghoniem G, Faruqui N, Elmissiry M, et al. Differential profile analysis of urinary cytokines in patients with overactive bladder. International urogynecology journal. 2011;22:953-61.
  • 6. Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. International urology and nephrology. 2010;42:629-35.
  • 7. Haylen BT, De Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourology and Urodynamics: Official Journal of the International Continence Society. 2010;29(1):4-20.
  • 8. Tarcan T, Mangır N, Özgür MÖ, et al. OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni. 2012;21(21):113-6.
  • 9. Saini R, Gonzalez RR, Te AE. Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. Current urology reports. 2008;9(4):314-9.
  • 10. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology. 2006;50(6):1306-15.
  • 11. Benli E. An examination of relationship between overactive bladder and C-reactive protein and erythrocyte sedimentation rate. The New Journal of Urology. 2023;18(1):33-40.
  • 12. Kupelian V, Rosen RC, Roehrborn CG, et al. Association of overactive bladder and C‐reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU international. 2012;110(3):401-7.
  • 13. Çulha MG, Değirmentepe RB, Özbir S, et al. Elevated neutrophil-to-lymphocyte ratio may be associated with overactive bladder patients. European Archives of Medical Research. 2020;36(2):125-9.
  • 14. Kim S, Park JH, Oh YH, et al. Correlation between neutrophil to lymphocyte ratio and overactive bladder in South Korean women: a community-based, cross-sectional study. BMJ open. 2021;11(10):e048309.
  • 15. Tyagi P, Tyagi V, Qu X, et al. Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. American Journal of Physiology-Renal Physiology. 2016;311(3):F548-F54.
  • 16. Pennycuff JF, Schutte SC, Hudson CO, et al. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder. Neurourology and urodynamics. 2017;36(3):740-4.
  • 17. Inamura S, Ito H, Shinagawa T, et al. Serum C‐reactive protein level is not associated with prostatic inflammation but with overactive detrusor in patients with benign prostatic hyperplasia. Neurourology and Urodynamics. 2019;38(6):1728-36.
Toplam 17 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Üroloji
Bölüm Araştırma Makaleleri
Yazarlar

Ozgur Ekıcı

Abdullah Gül 0000-0003-4002-4659

Ali Seydi Bozkurt

Ercüment Keskin 0000-0001-9618-8252

Volkan Çağlayan

Abdullah Erdoğan

Uğur Akgün

Omer Buyuktepe

Erken Görünüm Tarihi 15 Şubat 2024
Yayımlanma Tarihi 12 Şubat 2024
Gönderilme Tarihi 14 Ocak 2024
Kabul Tarihi 10 Şubat 2024
Yayımlandığı Sayı Yıl 2023 Cilt: 4 Sayı: 4

Kaynak Göster

Vancouver Ekıcı O, Gül A, Bozkurt AS, Keskin E, Çağlayan V, Erdoğan A, Akgün U, Buyuktepe O. INVESTIGATION OF INFLAMMATORY MARKER LEVELS IN OVERACTIVE BLADDER PATIENTS. Exp Appl Med Sci. 2024;4(4):601-9.

    22718  2043020542   20575   20690    20805   21108       22245 

22392  22684  22717